期刊文献+

Luffin P1-KDEL的构建、表达、纯化及鉴定 被引量:7

Construction,expression,and identification of Luffin P1-KDEL
下载PDF
导出
摘要 目的构建植物毒素Luffin P1的原核表达质粒PET32a(+)-Luffin P1,并对其进行诱导表达,以及表达蛋白的纯化及鉴定。方法采用基因工程技术将重组基因片段Luffin P1克隆到表达载体pET32a(+)中,经酶切及DNA序列分析正确后,转化至表达宿主菌BL21(DE3)中,经IPTG诱导表达Luffin P1融合蛋白,并用His标签抗体对该融合蛋白进行Western blot鉴定,对鉴定正确的融合蛋白进行纯化,肠激酶酶切及再纯化。结果成功的构建了原核表达载体pET32a(+)-Luffin P1,获得了纯度较高的Luffin P1蛋白。结论通过基因工程合成Luffin P1蛋白是成功的,并为进一步对Luffin P1功能研究及制备免疫毒素的弹头鉴定了实验基础。 Objective Luffin P1 as a new member of luffin family is an effective ribosome inactivating protein(RIP).In this study,we aimed to construct prokaryotic expression plasmid PET32a(+)-Luffin P1 for expressing,purifying,and identifying the expression protein Luffin P1.We subcloned a recombinant LuffinP1 DNA fragment into an expression plasmid pET32a(+),and identified the recombined plasmid by restriction enzyme digestion and DNA sequencing.After the recombinant plasmid was transformed into bacteria BL21(DE3),the expression of fusion protein Luffin P1 was induced by IPTG and identified by Western blotting using anti-His Ab,then the fusion protein was purified,digested by enterokinase,and re-purified.The new recombinant plasmid pET32a(+)-Luffin P1 was successfully constructed,and the correct fusion protein of Luffin P1 was highly purified.These results imply that Luffin P1 protein cand be acquired through genetic engineering, which provides a experimental basis for function research of Luffin P1 and production of immunotoxin warheads.
出处 《免疫学杂志》 CAS CSCD 北大核心 2010年第1期16-20,共5页 Immunological Journal
基金 国家自然科学基金资助项目(30771933) 重庆市科研基金资助项目(CSTC 2007BB5089) 解放军324医院 院管课题
关键词 免疫毒素 核糖体失活蛋白 Luffin P1 Immunotoxin Ribosome-inactivating protein Luffin P1
  • 相关文献

参考文献10

  • 1Pastan I, Hassan R, Fitzgerald D J, et al. Immunotoxin therapy of cancerCJI [J]. Nat Rev Cancer, 2006, 6 (7): 559-565.
  • 2Li F, Yang XX, Xia HC, et al. Purification and characterization of Luffin P1, a ribosome-inactivating pepfide from the Seeds of cykubdricaCJI [J]. Peptides, 2003, 24(6): 799-805.
  • 3刘树雷,何威,王儒鹏,吴军,张小容,赵云.重组免疫毒素hIL2-Luffin P1的构建、表达及鉴定[J].免疫学杂志,2008,24(3):315-317. 被引量:2
  • 4Kreitman RJ. Recombinant immunotoxins for the treatment of haematological malignanciesCJI [J]. Expert Opin Biol Ther, 2004, 4(7): 1115-1128.
  • 5王儒鹏,何威,贺伟峰,张小容,刘树雷,吴军.重组免疫毒素对同种小鼠皮肤移植排斥反应的抑制作用[J].免疫学杂志,2008,24(3):308-310. 被引量:3
  • 6Parkash A. Purification and characterization of charantin, a napin-like ribosome-inactivating pepfide from bitter gourd (Momordica charantia) seedsCJI [J]. J Pept Res, 2002, 59(5): 197-202.
  • 7Parkash A, Ng TB, Tso WW. Isolation and characterization of luffacylin, a ribosome inactivating peptide with anti-fungal activity from sponge gourd (Luffa cylindrica) seedsCJI [J]. Peptides, 2002, 23(6): 1019-1024.
  • 8Johannes L, Decaudin D. Protein toxins: intracellular trafficking for largeted therapyCJI [J]. Gene Ther, 2005,12 (18):1360-1368.
  • 9Chen A, Hu T, Mikoryak C, et al. Retrograde transport of protein toxins under conditions of COPI dysfunction [J]. Biochim Biophys Acta, 2002, 1589(2): 124-139.
  • 10Wang HX, Ng TB, Cheng CH. Contamination of ribosome inactivating proteins with ribonucleases, separated by affinity chromatography on red sepharoseCJI [J]. Prep Biochem Biotechnol, 2003, 33 (2) : 101 - 112.

二级参考文献20

  • 1王儒鹏,吴军,袁军,解志杰,贺伟峰,易绍萱,张小容.核糖体失活蛋白LuffinP1的构建*[J].贵阳医学院学报,2005,30(2):103-107. 被引量:2
  • 2王儒鹏,周丽娜,吴军,贺伟峰,易绍萱,陈希伟,张小容.重组免疫毒素hIL-2-LuffinP1的构建及表达[J].第三军医大学学报,2005,27(9):828-830. 被引量:5
  • 3吴蔚,杨康,白云,王婉瑜,李军,熊刚.蛇毒因子消耗补体对大鼠同种心脏移植急性排斥反应的影响[J].免疫学杂志,2006,22(1):61-64. 被引量:6
  • 4井申荣,邹全明,洪愉,毛旭虎.重组人IL-10融合蛋白的表达及其生物学活性测定[J].免疫学杂志,2006,22(4):399-401. 被引量:2
  • 5Descotes J. Methods of evaluating immunotoxicity [J]. Expert Opin Drug Metab Toxicol, 2006, 2(2): 249-259.
  • 6Chin KM, Foss FM. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox [ J]. Clin Lymphoma Myeloma, 2006, 7 (3): 199-204.
  • 7Psarras K, Ueda M, Tanabe M, et al. Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion[J]. Cytokine, 2000, 12(6) : 786 - 790.
  • 8Foss FM, Waldmarm TA. Interleukin-2 receptor-directed therapies for cutaneous lymphomas[J]. Hematol Oncol Clin Noah Am, 2003, 17(6) : 1 449- 1 458.
  • 9Querfeld C, Rosen ST, Guitart J, et al. Phase Ⅱ trial of subcutaneous injections of human recombinant intedeukin-2 for the treatment of mycosis fungoides and Sezary syndrome[ J]. J Am Acad Dermatol, 2007, 56 (4): 580-583.
  • 10Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer[J]. Nat Rev Cancer, 2006, 6 (7) : 559 - 565.

共引文献3

同被引文献54

引证文献7

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部